Bristol/ImClone's Erbitux Could Be A First-Line Head And Neck Cancer Submission
This article was originally published in The Pink Sheet Daily
Executive Summary
Companies are also pursuing possible use as a front-line non-small cell lung cancer treatment. The biologic is being studied as fist-line in colorectal cancer as well.
You may also be interested in...
Bristol/ImClone's Erbitux Clears FDA; Undergoing Two Confirmatory Trials
Erbitux is indicated for treatment of EGFR-expressing, metastatic colorectal carcinoma in combination with irinotecan or as monotherapy. Launch is expected within two weeks using product manufactured at Lonza Biologics facility.
Barr’s Expanded Thalidomide ANDA Could Increase Likelihood Of A Marketed Generic
Amended application includes 50 mg and 100 mg dosage forms, which are used in multiple myeloma.
User Fee Deal For Ad Review Funds Stems From PhRMA DTC Principles
A draft agreement between industry and FDA that would assess user fees for "advisory review" of broadcast direct-to-consumer ads prior to initial public dissemination had its genesis in the Pharmaceutical Research & Manufacturers of America's DTC guiding principles